{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:44:46Z","timestamp":1772495086802,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Treatment of latent tuberculosis infection (LTBI) decreases risk of progression to active tuberculosis. Traditional treatment regimens required either daily isoniazid for 9 months, with historically poor compliance, or 12-week directly observed therapy (DOT) with isoniazid and rifapentine, with improved compliance but additional challenges of coordinating weekly clinic visits, further complicated if patients must travel a great distance for care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Our referral area is complicated by congested traffic often resulting in one-way commutes, which can exceed 2 hours. These travel times would be prohibitive for conducting weekly in-clinic DOT. In an effort to improve access to DOT, we implemented TeleMedicine LTBI DOT (vDOT) within a military pediatric infectious diseases clinic. Patients aged 24 months or older diagnosed with LTBI were referred for possible enrollment into our vDOT clinic. All patients without contraindications for receiving isoniazid and\/or rifapentine were offered LTBI treatment via weekly vDOT or daily treatment with isoniazid or rifampin. The first visit for vDOT patients was performed in person to discuss treatment options, demonstrate use of TeleMedicine software, and ensure the patient was able to take the medications. Baseline information about patients and travel time to our facility was determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>To date, 16 patients have completed LTBI therapy using vDOT. Average one-way travel time to our facility for patients was 51 minutes. Actual time spent in most vDOT encounters was less than 10 minutes. Appointments were arranged to take place outside usual school and work hours so patients could complete vDOT with minimal interruptions to daily life, resulting in 100% treatment compliance and completion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Conducting LTBI DOT using TeleMedicine is a viable and time-saving measure that still allows for high levels of patient compliance and treatment completion while minimizing interruptions to academic and work schedules.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa300","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:51:15Z","timestamp":1611625875000},"page":"25-31","source":"Crossref","is-referenced-by-count":11,"title":["Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infection"],"prefix":"10.1093","volume":"186","author":[{"given":"Megan L","family":"Donahue","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D","family":"Eberly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rajnik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"issue":"10","key":"2021012914144904400_R1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modeling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"2021012914144904400_R2","article-title":"Global tuberculosis report 2019","author":"World Health Organization"},{"key":"2021012914144904400_R3","article-title":"Global strategy and targets for tuberculosis prevention, care and control after 2015","author":"World Health Organization"},{"key":"2021012914144904400_R4","article-title":"Towards TB elimination: an action framework for low-incidence countries","author":"World Health Organization"},{"key":"2021012914144904400_R5","article-title":"Centers for Disease Control and Prevention, 2018","author":"Division of tuberculosis elimination strategic plan 2016-2020"},{"key":"2021012914144904400_R6","author":"Treatment regimens for latent tuberculosis (LTBI). Centers for Disease Control and Prevention, 2016"},{"issue":"23","key":"2021012914144904400_R7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2021012914144904400_R8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City Health Department clinics","volume":"62","author":"Stennis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"25","key":"2021012914144904400_R9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"2021012914144904400_R10","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1086\/324506","article-title":"The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project","volume":"33","author":"DeMaio","year":"2011","journal-title":"CID"},{"issue":"11","key":"2021012914144904400_R11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050155","article-title":"Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation","volume":"7","author":"Wade","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2021012914144904400_R12","doi-asserted-by":"crossref","DOI":"10.17269\/cjph.104.3869","article-title":"The use of videophone for directly observed therapy for the treatment of tuberculosis","volume":"104","author":"Gassanov","year":"2013","journal-title":"Can J Public Health"},{"issue":"3","key":"2021012914144904400_R13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1183\/09031936.00011015","article-title":"Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective","volume":"46","author":"Mirsaeidi","year":"2015","journal-title":"Eur Resp J"},{"issue":"5","key":"2021012914144904400_R14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5588\/ijtld.15.0738","article-title":"Enhancing management of tuberculosis treatment with video directly observed therapy in New York City","volume":"20","author":"Chuck","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"2021012914144904400_R15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/PHH.0000000000000627","article-title":"A national survey on the use of electronic directly observed therapy for treatment of tuberculosis","volume":"24","author":"Macaraig","year":"2018","journal-title":"J Public Health Manag Pract"},{"issue":"3","key":"2021012914144904400_R16","doi-asserted-by":"crossref","DOI":"10.2196\/13411","article-title":"Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: a single-arm, prospective feasibility study","volume":"3","author":"Holzman","year":"2019","journal-title":"JMIR Form Res"},{"issue":"9","key":"2021012914144904400_R17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1089\/tmj.2019.0190","article-title":"Telemedicine technologies and tuberculosis management: a randomized control trial","volume":"26","author":"Guo","year":"2019","journal-title":"Telemed J E Health"},{"issue":"14","key":"2021012914144904400_R18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.15585\/mmwr.mm6614a3","article-title":"Use of video directly observed therapy for treatment of latent tuberculosis infection \u2013 Johnson County, Kansas, 2015","volume":"66","author":"Holzschuh","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"2021012914144904400_R19","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.9825","article-title":"Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study","volume":"20","author":"Lam","year":"2018","journal-title":"J Med Internet Res"},{"key":"2021012914144904400_R20","author":"Tuberculosis Country Profiles. World Health Organization, 2018"},{"issue":"5","key":"2021012914144904400_R21","first-page":"4","article-title":"Tuberculosis trends in the U.S. armed forces, active component, 1998-2012","volume":"20","author":"Mancuso","year":"2013","journal-title":"MSMR"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/Supplement_1\/25\/36145253\/usaa300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/Supplement_1\/25\/36145253\/usaa300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T14:15:01Z","timestamp":1611929701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/Supplement_1\/25\/6119440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":21,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa300","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]}}}